Neuren Pharmaceuticals Buyback Yield % Related Terms
Neuren Pharmaceuticals Buyback Yield % Historical Data
* Premium members only.
The historical data trend for Neuren Pharmaceuticals's Buyback Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ASX:NEU vs VRTX, REGN, ALNY: Buyback Yield % Comparison
For the Biotechnology subindustry, Neuren Pharmaceuticals's Buyback Yield %, along with its competitors' market caps and Buyback Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Neuren Pharmaceuticals Buyback Yield % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Neuren Pharmaceuticals's Buyback Yield % distribution charts can be found below:
* The bar in red indicates where Neuren Pharmaceuticals's Buyback Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Neuren Pharmaceuticals (ASX:NEU) has a Buyback Yield % of 1.59 as of Jul. 12, 2026. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on Neuren Pharmaceuticals and its competitors. According to the industry distribution chart, Neuren Pharmaceuticals ranks #39 out of 742 companies in the Biotechnology industry, placing it in the top 5.3%.
Is Neuren Pharmaceuticals' Buyback Yield % too high?
Neuren Pharmaceuticals' current Buyback Yield % is 1.59. Based on the distribution chart, Neuren Pharmaceuticals ranks #39 out of 742 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Neuren Pharmaceuticals has a GF Score™ of 54/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Neuren Pharmaceuticals' Buyback Yield % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Neuren Pharmaceuticals ranks #39 out of 742 companies for Buyback Yield %. This places Neuren Pharmaceuticals in the top 5% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Buyback Yield % for a Biotechnology company?
A good Buyback Yield % depends on the Biotechnology industry context. However, Buyback Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Buyback Yield % mean?
A high Buyback Yield % can signal that a stock is expensive relative to its fundamentals. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on Neuren Pharmaceuticals and its competitors. Neuren Pharmaceuticals's current Buyback Yield % is 1.59. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Neuren Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Neuren Pharmaceuticals (ASX:NEU) is currently considered Significantly Overvalued. The stock's GF Value™ is A$7.20, compared to a current price of A$16.52 — trading 129.4% above its estimated fair value. The current Buyback Yield % is 1.59. Neuren Pharmaceuticals' overall GF Score™ is 54/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Buyback Yield % calculated?
Buyback Yield % is calculated from a company's financial statements. For Neuren Pharmaceuticals (ASX:NEU), the current Buyback Yield % is 1.59 as of Jul. 12, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Neuren Pharmaceuticals (ASX:NEU) Overvalued in 2026?
Based on GuruFocus' analysis, Neuren Pharmaceuticals stock appears to be overvalued.
The current stock price of A$16.52 is trading 129.4% above its estimated GF Value™ of A$7.20.
GuruFocus considers Neuren Pharmaceuticals to be Significantly Overvalued.
Key valuation signals for ASX:NEU:
Buyback Yield %: 1.59
GF Value™: A$7.20 vs. price of A$16.52 (129.4% above fair value)
No single metric tells the full story. See the ASX:NEU stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Neuren Pharmaceuticals Ltd is a biopharmaceutical company, which engages in the development of new therapies for brain injury, neurodevelopment disorders. Its drugs target symptoms resulting from acute traumatic brain injury, as well as symptoms of chronic conditions, such as Rett syndrome and Fragile X syndrome. The Group has two reportable operating segments, Commercial Products and Research and Development. It derives maximum revenue from Commercial Products.
54GF Score
Get the complete analysis for ASX:NEU
Buyback Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:NEU has been successfully added to your 
